CN104640545A - 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法 - Google Patents

包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法 Download PDF

Info

Publication number
CN104640545A
CN104640545A CN201380042815.XA CN201380042815A CN104640545A CN 104640545 A CN104640545 A CN 104640545A CN 201380042815 A CN201380042815 A CN 201380042815A CN 104640545 A CN104640545 A CN 104640545A
Authority
CN
China
Prior art keywords
compound
braf
pharmaceutically acceptable
acceptable salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380042815.XA
Other languages
English (en)
Chinese (zh)
Inventor
G.布雷
I.T.钱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49035547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104640545(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201910437096.0A priority Critical patent/CN110251512A/zh
Publication of CN104640545A publication Critical patent/CN104640545A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • Strategic Management (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Marketing (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Game Theory and Decision Science (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
CN201380042815.XA 2012-08-17 2013-08-15 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法 Pending CN104640545A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910437096.0A CN110251512A (zh) 2012-08-17 2013-08-15 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US61/684,673 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US61/705,575 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US61/706,026 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US61/722,725 2012-11-05
US201361780708P 2013-03-13 2013-03-13
US61/780,708 2013-03-13
PCT/EP2013/067050 WO2014027056A1 (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910437096.0A Division CN110251512A (zh) 2012-08-17 2013-08-15 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法

Publications (1)

Publication Number Publication Date
CN104640545A true CN104640545A (zh) 2015-05-20

Family

ID=49035547

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380042815.XA Pending CN104640545A (zh) 2012-08-17 2013-08-15 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法
CN201910437096.0A Pending CN110251512A (zh) 2012-08-17 2013-08-15 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910437096.0A Pending CN110251512A (zh) 2012-08-17 2013-08-15 包括给药cobimetinib和威罗菲尼的黑色素瘤的组合疗法

Country Status (31)

Country Link
US (3) US11087354B2 (cg-RX-API-DMAC7.html)
EP (1) EP2884979B1 (cg-RX-API-DMAC7.html)
JP (2) JP6335169B2 (cg-RX-API-DMAC7.html)
KR (6) KR20240146112A (cg-RX-API-DMAC7.html)
CN (2) CN104640545A (cg-RX-API-DMAC7.html)
AU (1) AU2013304021B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015003418A2 (cg-RX-API-DMAC7.html)
CA (2) CA2928396A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000345A1 (cg-RX-API-DMAC7.html)
CO (1) CO7180225A2 (cg-RX-API-DMAC7.html)
DK (1) DK2884979T3 (cg-RX-API-DMAC7.html)
EA (1) EA033573B1 (cg-RX-API-DMAC7.html)
ES (1) ES2743427T3 (cg-RX-API-DMAC7.html)
HK (1) HK1206605A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191533T1 (cg-RX-API-DMAC7.html)
HU (1) HUE044789T2 (cg-RX-API-DMAC7.html)
IL (1) IL237065B (cg-RX-API-DMAC7.html)
LT (1) LT2884979T (cg-RX-API-DMAC7.html)
MX (1) MX367970B (cg-RX-API-DMAC7.html)
MY (1) MY180613A (cg-RX-API-DMAC7.html)
NZ (1) NZ744862A (cg-RX-API-DMAC7.html)
PE (1) PE20151156A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500186A1 (cg-RX-API-DMAC7.html)
PL (1) PL2884979T3 (cg-RX-API-DMAC7.html)
PT (1) PT2884979T (cg-RX-API-DMAC7.html)
RS (1) RS59113B1 (cg-RX-API-DMAC7.html)
SG (3) SG10201708494QA (cg-RX-API-DMAC7.html)
SI (1) SI2884979T1 (cg-RX-API-DMAC7.html)
UA (1) UA114923C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014027056A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500348B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135854A (zh) * 2015-06-30 2018-06-08 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
CN109879855A (zh) * 2019-03-26 2019-06-14 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
CN115551509A (zh) * 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015191986A1 (en) * 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
BR112017025045A2 (pt) * 2015-05-22 2018-08-07 Plexxikon Inc plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
BR112018008882A8 (pt) 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
WO2017087851A1 (en) * 2015-11-19 2017-05-26 Genentech, Inc. Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
WO2018064299A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
CN117940130A (zh) 2021-03-09 2024-04-26 基因泰克公司 用于脑癌治疗的贝伐拉非尼
CN117561062A (zh) 2021-04-06 2024-02-13 基因泰克公司 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法
WO2023220067A1 (en) * 2022-05-09 2023-11-16 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
WO2025008650A1 (en) * 2023-07-03 2025-01-09 Országos Onkológiai Intézet Cse inhibitor for use in the treatment of a tumor in combination with a mapk inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102361870A (zh) * 2009-04-03 2012-02-22 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005047542A1 (en) 2003-10-16 2005-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ret調節剤の開発のための化合物および方法
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
SI1913157T2 (sl) 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
PL2073810T3 (pl) * 2006-09-13 2012-01-31 Takeda Pharmaceuticals Co Zastosowanie 2-6-(3-amino-piperydyn-1-ylo)-3-metylo-2,4-diokso-3,4-dihydro-2H-pirymidyn-1-ylometylo-4-fluoro-benzonitrylu do leczenia cukrzycy, raka, zaburzeń autoimmunizacyjnych i zakażeń HIV
EP2074226A2 (en) 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
PL2412828T3 (pl) 2007-03-13 2013-11-29 Amgen Inc Mutacje K-ras i B-raf i terapia przeciwciałami anty-EGFr
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US20110003859A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN102859355B (zh) 2009-08-24 2015-10-07 基因泰克公司 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2488184A4 (en) 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
AU2010314287A1 (en) * 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
WO2011104694A2 (en) 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
CN103370064A (zh) * 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
WO2012061683A2 (en) 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
CN104689318A (zh) 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权(第2号)有限公司 使用braf抑制剂的治疗方法
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102361870A (zh) * 2009-04-03 2012-02-22 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREAS R BAUDY ET AL.: "FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973", 《EJNMMI RESEARCH》, vol. 2, no. 22, 31 May 2012 (2012-05-31), pages 1 - 10, XP 055084944 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135854A (zh) * 2015-06-30 2018-06-08 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
CN114177157A (zh) * 2015-06-30 2022-03-15 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
TWI795344B (zh) * 2015-06-30 2023-03-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
CN114177157B (zh) * 2015-06-30 2024-08-02 基因泰克公司 含有药物的立即释放片剂和用于形成片剂的方法
CN109879855A (zh) * 2019-03-26 2019-06-14 中国医学科学院医药生物技术研究所 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
CN115551509A (zh) * 2020-05-12 2022-12-30 诺华股份有限公司 包含craf抑制剂的治疗组合

Also Published As

Publication number Publication date
WO2014027056A1 (en) 2014-02-20
LT2884979T (lt) 2019-09-10
DK2884979T3 (da) 2019-09-02
EP2884979B1 (en) 2019-06-26
KR20190057421A (ko) 2019-05-28
RS59113B1 (sr) 2019-09-30
EA033573B1 (ru) 2019-11-06
US20220172244A1 (en) 2022-06-02
JP2017160214A (ja) 2017-09-14
EA201590262A1 (ru) 2015-06-30
EP2884979A1 (en) 2015-06-24
US20240046303A1 (en) 2024-02-08
KR20220165811A (ko) 2022-12-15
HUE044789T2 (hu) 2019-11-28
KR20210108502A (ko) 2021-09-02
HRP20191533T1 (hr) 2019-11-29
CN110251512A (zh) 2019-09-20
PL2884979T3 (pl) 2019-11-29
PH12015500186A1 (en) 2015-04-06
JP2015531763A (ja) 2015-11-05
KR20150038068A (ko) 2015-04-08
AU2013304021A1 (en) 2015-02-12
CA2879252A1 (en) 2014-02-20
AU2013304021B2 (en) 2016-09-15
US12354130B2 (en) 2025-07-08
ES2743427T3 (es) 2020-02-19
BR112015003418A2 (pt) 2017-07-04
CA2879252C (en) 2017-10-10
IL237065A0 (en) 2015-03-31
KR20240146112A (ko) 2024-10-07
UA114923C2 (uk) 2017-08-28
US11783366B2 (en) 2023-10-10
ZA201500348B (en) 2019-07-31
KR20170044759A (ko) 2017-04-25
CO7180225A2 (es) 2015-02-09
NZ744862A (en) 2019-06-28
PT2884979T (pt) 2019-09-04
MX2015002031A (es) 2015-06-05
CL2015000345A1 (es) 2015-05-22
HK1206605A1 (en) 2016-01-15
PE20151156A1 (es) 2015-08-19
MY180613A (en) 2020-12-03
JP6335169B2 (ja) 2018-05-30
US20140093568A1 (en) 2014-04-03
US11087354B2 (en) 2021-08-10
SG11201500582UA (en) 2015-04-29
IL237065B (en) 2020-07-30
SG10201913359TA (en) 2020-02-27
CA2928396A1 (en) 2014-02-20
SI2884979T1 (sl) 2019-10-30
SG10201708494QA (en) 2017-11-29
MX367970B (es) 2019-09-11

Similar Documents

Publication Publication Date Title
US12354130B2 (en) Combination therapies
JP2015531763A5 (cg-RX-API-DMAC7.html)
Gutkind et al. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
Slamon et al. Ribociclib plus endocrine therapy in early breast cancer
Kleer et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression
US20230210852A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
Minor et al. Sunitinib therapy for melanoma patients with KIT mutations
US20160331750A1 (en) Methods for treatment of lymphomas with mutations in cell cycle genes
Ibrahim et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
Shi et al. The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification
WO2012103060A1 (en) Method of administration and treatment
Ksienski Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors
Tsushima et al. Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations
HK40013180A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
GUINIGUNDO The Role of Biomarkers in Guiding Clinical Decision-Making in Oncology
TW202532065A (zh) 治療乳癌之組合療法
CN116981462A (zh) 索托拉西布给药方案
Trial Efficacy of Imatinib in Aggressive Fibromatosis: Results of

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206605

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150520

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206605

Country of ref document: HK